Interestingly, TNF-antagonists used for the therapy of autoimmune disorders may be viable therapeutics to reduce BPH incidence in patients with autoimmune diseases and decrease localized inflammation within the prostate [16]. Here, TNF is linked to benign prostatic hyperplasia.